文献速递肝病消化道肿瘤与早癌

在乙型肝炎流行地区,肝细胞癌监测的强度决定危险人群的生存

Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis B-endemic area.
PubMed 文献 · Aliment Pharmacol Ther · 2018-04-02

该回顾性队列研究纳入韩国一家三级医院2005至2012年连续新诊断的1402例肝细胞癌患者,主要终点为总生存,并校正提前时间偏倚(逗留时间=140天)。与未监测组相比,规律监测组死亡风险显著降低(校正风险比0.69,95%CI 0.57-0.83),但不规律监测组无显著差异(校正风险比0.94,95%CI 0.69-1.28)。

要点

  • 规律监测组较未监测组死亡风险显著降低:校正风险比0.69(95%CI 0.57-0.83)
  • 不规律监测组与未监测组相比,死亡风险无显著差异:校正风险比0.94(95%CI 0.69-1.28)
  • 规律监测组诊断时早期比例64.4%,高于不规律监测组的40.4%和未监测组的26.9%

核心结论

  • 肝细胞癌监测通过早期诊断和根治性治疗与更长生存相关。
  • 规律监测具有显著的生存优势,但不规律监测无显著生存优势。

研究设计与样本

  • 回顾性队列研究,纳入韩国一家三级医院2005至2012年连续新诊断的1402例肝细胞癌患者。
  • 主要终点为总生存,校正提前时间偏倚(逗留时间=140天)并进行敏感性分析。

主要发现

  • 最常见病因为乙型肝炎(80.4%),肝硬化占78.2%。
  • 规律监测组诊断时(极)早期比例为64.4%,高于不规律监测组的40.4%和未监测组的26.9%(均P<0.001)。
  • 规律监测组接受根治性治疗的比例为52.4%,高于不规律监测组的39.4%和未监测组的23.3%(均P<0.001)。
  • 与未监测组相比,规律监测组校正混杂因素和提前时间后的死亡风险显著降低(校正风险比0.69,95%CI 0.57-0.83),不规律监测组无显著差异(校正风险比0.94,95%CI 0.69-1.28)。
  • 在肝硬化患者或Child-Pugh A/B级患者中,各组间死亡风险降低的结果相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data are insufficient regarding the survival benefit of surveillance for hepatocellular carcinoma (HCC). AIM: To investigate the effectiveness of HCC surveillance in a hepatitis B-endemic population. METHODS: This retrospective cohort study included 1402 consecutive patients who were newly diagnosed with HCC between 2005 and 2012 at a single tertiary hospital in Korea. The primary endpoint was overall survival. Lead-time and length-time biases were adjusted (sojourn time = 140 days) and sensitivity analyses were performed. RESULTS: The most common aetiology was hepatitis B (80.4%). Cirrhosis was present in 78.2%. HCC was diagnosed during regular surveillance (defined as mean interval of ultrasonography <8 months, n = 834), irregular surveillance (n = 104) or nonsurveillance (n = 464). Patients in the regular surveillance group were diagnosed at earlier stages ([very] early stage, 64.4%) than the irregular surveillance (40.4%) or nonsurveillance (26.9%) groups and had more chance for curative treatments (52.4%) than the irregular surveillance (39.4%) or nonsurveillance (23.3%) groups (all P < 0.001). Mortality risk was significantly lower in the regular surveillance group (adjusted hazard ratio [aHR], 0.69; 95% [CI], 0.57-0.83) but not in the irregular surveillance group (aHR, 0.94; 95% CI, 0.69-1.28) compared with the nonsurveillance group after adjusting for confounding factors and lead-time. When the subjects were restricted to cirrhotic patients or Child-Pugh class A/B patients, similar results were obtained for mortality risk reduction between groups. CONCLUSIONS: HCC surveillance was associated with longer survival owing to earlier diagnosis and curative treatment. Survival advantage was significant with regular surveillance but not with irregular surveillance.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Kim HY, Nam JY, Lee JH, et al. Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis B-endemic area. Aliment Pharmacol Ther. 2018. PMID: 29611209. doi:10.1111/apt.14623

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。